Field Medical's FieldForce™ Ablation System Earns FDA TAP Pilot Acceptance and Breakthrough Device Designation for the Treatment of Ventricular Tachycardia.

Field Medical, Inc. California Vermont

First and only contact force pulsed field ablation (PFA) system engineered to revolutionize care for the hundreds of thousands at risk of death from ventricular tachycardia (VT).FDA's TAP Pilot and Breakthrough Device Designation are awarded to medical devices that could provide more effective treatment compared to existing approved treatments, reflecting the agency's commitment to expediting patient access to innovative, safe, and effective therapies.and X.

The FieldForce™ PFA Ablation System is an investigational device and is limited by Federal (or United States) Law to investigational use.

Media Contact
Holly Windler
619.929.1275

References:
Mason, J., et al. (2022). "Trends in Sudden Cardiac Death Due to Ventricular Tachycardia and Fibrillation in the United States." Circulation Research.
Kircher, A., et al. (2023). "Efficacy of Antiarrhythmic Medications in the Treatment of Ventricular Tachycardia: A Review." Journal of the American College of Cardiology.
Sapp, J., et al. (2024). "Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia." The New England Journal of Medicine. DOI: 10.1056/NEJMoa2409501.

Photo - https://mma.prnewswire.com/media/2574172/Field_Medical_FieldForce_PFA___Full_Thickness_Endocardial_Ablation.jpg
Logo - https://mma.prnewswire.com/media/2574173/Field_Medical_Logo_Block_WhiteOnBlack_Logo.jpg 

View original content:https://www.prnewswire.co.uk/news-releases/field-medicals-fieldforce-ablation-system-earns-fda-tap-pilot-acceptance-and-breakthrough-device-designation-for-the-treatment-of-ventricular-tachycardia-302323623.html